The effects of Bu Yang Huan Wu Tang on poststroke epilepsy: A nationwide matched study

Shu Wen Weng, Ta Liang Chen, Chun Chieh Yeh, Hsin Long Lane, Chien Chang Liao, Chun Chuan Shih

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective: To compare the long-term risk of epilepsy in stroke patients who use Bu Yang Huan Wu Tang (BYHWT) and those who do not. Methods: In the Taiwanese national insurance claims data, we identified newly diagnosed stroke patients receiving inpatient care in the years 2000–2004. Using propensity score-matched pairs to balance the baseline characteristics, we selected eligible stroke patients who did (n=8,971) and did not (n=8,971) receive BYHWT. These two groups were followed up until the end of 2009 to track the occurrence of epilepsy. We used Cox proportional hazard models to calculate the adjusted HRs and 95% CIs for post-stroke epilepsy during the follow-up period according to BYHWT use. Results: Compared with the control group, stroke patients with BYHWT had a reduced risk of epilepsy during the 5–9 years of the follow-up period (HR 0.69, 95% CI 0.61–0.77). The association between BYHWT and reduced post-stroke epilepsy was significant in various subgroups of stroke patients. There was a dose-dependent decrease in the frequency of epilepsy with increasing quantities of BYHWT use from 1 package (HR 0.77, 95% CI 0.66–0.90) to ≥6 packages (HR 0.52, 95% CI 0.42–0.65). Conclusion: Stroke patients who received BYHWT therapy had a reduced long-term risk of epilepsy, and the beneficial effect could be observed in various subgroups. However, future clinical trials will be necessary to corroborate the present findings and identify the biochemical mechanism involved.

Original languageEnglish
Pages (from-to)1839-1850
Number of pages12
JournalClinical Epidemiology
Volume10
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Epilepsy
Stroke
Propensity Score
bu-yang-huan-wu-tang
Insurance
Proportional Hazards Models
Inpatients
Clinical Trials
Control Groups

Keywords

  • Bu Yang Huan Wu Tang
  • Epilepsy
  • Long-term risk
  • Stroke

ASJC Scopus subject areas

  • Epidemiology

Cite this

The effects of Bu Yang Huan Wu Tang on poststroke epilepsy : A nationwide matched study. / Weng, Shu Wen; Chen, Ta Liang; Yeh, Chun Chieh; Lane, Hsin Long; Liao, Chien Chang; Shih, Chun Chuan.

In: Clinical Epidemiology, Vol. 10, 01.01.2018, p. 1839-1850.

Research output: Contribution to journalArticle

Weng, Shu Wen ; Chen, Ta Liang ; Yeh, Chun Chieh ; Lane, Hsin Long ; Liao, Chien Chang ; Shih, Chun Chuan. / The effects of Bu Yang Huan Wu Tang on poststroke epilepsy : A nationwide matched study. In: Clinical Epidemiology. 2018 ; Vol. 10. pp. 1839-1850.
@article{5b50b74bf452434cb4f5a87e9372ebee,
title = "The effects of Bu Yang Huan Wu Tang on poststroke epilepsy: A nationwide matched study",
abstract = "Objective: To compare the long-term risk of epilepsy in stroke patients who use Bu Yang Huan Wu Tang (BYHWT) and those who do not. Methods: In the Taiwanese national insurance claims data, we identified newly diagnosed stroke patients receiving inpatient care in the years 2000–2004. Using propensity score-matched pairs to balance the baseline characteristics, we selected eligible stroke patients who did (n=8,971) and did not (n=8,971) receive BYHWT. These two groups were followed up until the end of 2009 to track the occurrence of epilepsy. We used Cox proportional hazard models to calculate the adjusted HRs and 95{\%} CIs for post-stroke epilepsy during the follow-up period according to BYHWT use. Results: Compared with the control group, stroke patients with BYHWT had a reduced risk of epilepsy during the 5–9 years of the follow-up period (HR 0.69, 95{\%} CI 0.61–0.77). The association between BYHWT and reduced post-stroke epilepsy was significant in various subgroups of stroke patients. There was a dose-dependent decrease in the frequency of epilepsy with increasing quantities of BYHWT use from 1 package (HR 0.77, 95{\%} CI 0.66–0.90) to ≥6 packages (HR 0.52, 95{\%} CI 0.42–0.65). Conclusion: Stroke patients who received BYHWT therapy had a reduced long-term risk of epilepsy, and the beneficial effect could be observed in various subgroups. However, future clinical trials will be necessary to corroborate the present findings and identify the biochemical mechanism involved.",
keywords = "Bu Yang Huan Wu Tang, Epilepsy, Long-term risk, Stroke",
author = "Weng, {Shu Wen} and Chen, {Ta Liang} and Yeh, {Chun Chieh} and Lane, {Hsin Long} and Liao, {Chien Chang} and Shih, {Chun Chuan}",
year = "2018",
month = "1",
day = "1",
doi = "10.2147/CLEP.S175677",
language = "English",
volume = "10",
pages = "1839--1850",
journal = "Clinical Epidemiology",
issn = "1179-1349",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - The effects of Bu Yang Huan Wu Tang on poststroke epilepsy

T2 - A nationwide matched study

AU - Weng, Shu Wen

AU - Chen, Ta Liang

AU - Yeh, Chun Chieh

AU - Lane, Hsin Long

AU - Liao, Chien Chang

AU - Shih, Chun Chuan

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Objective: To compare the long-term risk of epilepsy in stroke patients who use Bu Yang Huan Wu Tang (BYHWT) and those who do not. Methods: In the Taiwanese national insurance claims data, we identified newly diagnosed stroke patients receiving inpatient care in the years 2000–2004. Using propensity score-matched pairs to balance the baseline characteristics, we selected eligible stroke patients who did (n=8,971) and did not (n=8,971) receive BYHWT. These two groups were followed up until the end of 2009 to track the occurrence of epilepsy. We used Cox proportional hazard models to calculate the adjusted HRs and 95% CIs for post-stroke epilepsy during the follow-up period according to BYHWT use. Results: Compared with the control group, stroke patients with BYHWT had a reduced risk of epilepsy during the 5–9 years of the follow-up period (HR 0.69, 95% CI 0.61–0.77). The association between BYHWT and reduced post-stroke epilepsy was significant in various subgroups of stroke patients. There was a dose-dependent decrease in the frequency of epilepsy with increasing quantities of BYHWT use from 1 package (HR 0.77, 95% CI 0.66–0.90) to ≥6 packages (HR 0.52, 95% CI 0.42–0.65). Conclusion: Stroke patients who received BYHWT therapy had a reduced long-term risk of epilepsy, and the beneficial effect could be observed in various subgroups. However, future clinical trials will be necessary to corroborate the present findings and identify the biochemical mechanism involved.

AB - Objective: To compare the long-term risk of epilepsy in stroke patients who use Bu Yang Huan Wu Tang (BYHWT) and those who do not. Methods: In the Taiwanese national insurance claims data, we identified newly diagnosed stroke patients receiving inpatient care in the years 2000–2004. Using propensity score-matched pairs to balance the baseline characteristics, we selected eligible stroke patients who did (n=8,971) and did not (n=8,971) receive BYHWT. These two groups were followed up until the end of 2009 to track the occurrence of epilepsy. We used Cox proportional hazard models to calculate the adjusted HRs and 95% CIs for post-stroke epilepsy during the follow-up period according to BYHWT use. Results: Compared with the control group, stroke patients with BYHWT had a reduced risk of epilepsy during the 5–9 years of the follow-up period (HR 0.69, 95% CI 0.61–0.77). The association between BYHWT and reduced post-stroke epilepsy was significant in various subgroups of stroke patients. There was a dose-dependent decrease in the frequency of epilepsy with increasing quantities of BYHWT use from 1 package (HR 0.77, 95% CI 0.66–0.90) to ≥6 packages (HR 0.52, 95% CI 0.42–0.65). Conclusion: Stroke patients who received BYHWT therapy had a reduced long-term risk of epilepsy, and the beneficial effect could be observed in various subgroups. However, future clinical trials will be necessary to corroborate the present findings and identify the biochemical mechanism involved.

KW - Bu Yang Huan Wu Tang

KW - Epilepsy

KW - Long-term risk

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=85062707994&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062707994&partnerID=8YFLogxK

U2 - 10.2147/CLEP.S175677

DO - 10.2147/CLEP.S175677

M3 - Article

AN - SCOPUS:85062707994

VL - 10

SP - 1839

EP - 1850

JO - Clinical Epidemiology

JF - Clinical Epidemiology

SN - 1179-1349

ER -